Adaptation to the Reality of Latin America of the NASPGHAN/ESPGHAN 2016 Guidelines on the Diagnosis, Prevention, and Treatment of <i>Helicobacter pylori</i> Infection in Pediatrics

Harris, Paul; Lucero, Yalda; Pierre, Reinaldo

doi:10.1097/mpg.0000000000003156

Cited by 4 publications

(27 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Berücksichtigt wurde die Literatur seit 2015. Eingegangen in diese Aktualisierung sind die Evidenz-basierten Leitlinien der Europäischen und Nordamerikanischen Gesellschaften für Pädiatrische Gastroenterologie, Hepatologie und Ernährung (ESPGHAN und NASPGHAN) [464], an der sich auch die Lateinamerikanische Leitlinie [465] orientiert, sowie die aktualisierte Japanische Leitlinie für Kinder und Jugendliche [466]. Bei den Empfehlungen ist zu berücksichtigen, dass die Entscheidungen zur Diagnostik und Therapie einer H. pylori-Infektion stark vom Alter des Patienten (Vorschulkind, Kind oder Teenager) abhängen sowie durch Ängste und Wünsche der Eltern für oder gegen eine H. pylori-Eradikationstherapie beeinflusst werden.…”

Section: Kommentarunclassified

Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Juli 2022 – AWMF-Registernummer: 021–001

2023

Z Gastroenterol

View full text Add to dashboard Cite

Section: Kommentarunclassified

Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Juli 2022 – AWMF-Registernummer: 021–001

2023

Z Gastroenterol

View full text Add to dashboard Cite

“…Quadruple therapies (either BQT or CT) were also suggested as empirical first-line treatments for adults and children. 2,8–10,39…”

Section: Therapeutic Regimen Combinationsmentioning

confidence: 99%

“…Since current evidence indicates that H. pylori infection does not cause symptoms in the absence of peptic ulcer disease and no substantial evidence has been documented regarding the health benefits of treatment in eliminating the infection in children, ESPGHAN/NASPGHAN, LASPGHAN, and JSPHGAN guidelines do not recommend ‘test and treat’ strategy. 8–10…”

Section: Therapeutic Regimen Combinationsmentioning

confidence: 99%

“…Overall, the following treatment regimens are shared by ESPGHAN/NASPGHAN, LASPGHAN, JSPGHAN, and Korean guidelines. 8–11…”

Section: Therapeutic Regimen Combinationsmentioning

confidence: 99%

“…Again, if H. pylori infection is incidentally diagnosed during gastroscopy performed for an unrelated clinical suspicion, the subsequent eradication treatment should be considered only after a careful discussion of the risks and benefits with parents. 8–10…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic eradication choices inHelicobacter pyloriinfection in children

Manfredi

Gargano

Gismondi

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Current recommendations on Helicobacter pylori ( H. pylori) eradication in children differ from adults. In H. pylori-infected adults, the eradication is always recommended because of the risk to develop gastrointestinal and non-gastrointestinal associated diseases. Instead, before treating infected children, we should consider all the possible causes and not merely focus on H. pylori infection. Indeed, pediatric international guidelines do not recommend the test and treat strategy in children. Therefore, gastroscopy with antimicrobial susceptibility testing by culture on gastric biopsies should be performed before starting the eradication therapy in children to better evaluate all the possible causes of the symptomatology and to increase the eradication rate. Whether antibiotic susceptibility testing is not available, gastroscopy is anyway recommended to better set any possible cause of symptoms and not simply focus on the presence of H. pylori. In children the lower antibiotics availability compared to adults forces to treat based on antimicrobial susceptibility testing to minimize the unsuccessful rates. The main antibiotics used in children are amoxicillin, clarithromycin, and metronidazole in various combinations. In empirical treatment, triple therapy for 14 days based either on local antimicrobial susceptibility or on personal antibiotic history is generally recommended. Triple therapy with high dose of amoxicillin is a valid alternative choice, either in double resistance or in second-line treatment. Moving from therapeutic regimens used in adults, we could also select quadruple therapy with or without bismuth salts. However, all the treatment regimens often entail unpleasant side effects and lower compliance in children. In this review, the alternative and not yet commonly used therapeutic choices in children were also analyzed.

show abstract

Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Fischbach,

Bornschein,

Hoffmann

et al. 2024

Z Gastroenterol

View full text Add to dashboard Cite

Responsible organisation 263 1.2 Scope of application and rationale for the selected guideline topic 263 1.3 Aim of the guideline 264 1.4 Area of care 264 1.5 User target group 264 1.6 Composition of the guideline committee and participation of interest groups 264 1.7 The following organisations and professional bodies contributed to this guideline 264 1.8 Representativeness of the guideline committee: patient contribution 265 2 Methods 266 2.1 Evidence synthesis 266 2.1.1 Methodology 266 2.2 External validation and approval 266 2.2.1 Approval by the executive boards of the publishing professional societies/organisations 266 2.2.2 Editorial independence and funding of the guideline 266 2.2.3 Conflict of interests policy 266 2.3 Distribution and implementation of the guideline 267 2.3.1 Concept for distribution and implementation 267 2.3.2 Period of validity and update process 267 2.4 Editorial Note 267 2.4.1 Participatory decision-making 267 2.5 Special considerations 267 3 Guideline -Preamble 267 4 Guideline -Topic complex 1: Epidemiology 267 5 Guideline -Topic complex 2: Diagnosis 271 6 Guideline -Topic complex 3: Indication for diagnostic testing 276

show abstract

Adaptation to the Reality of Latin America of the NASPGHAN/ESPGHAN 2016 Guidelines on the Diagnosis, Prevention, and Treatment of Helicobacter pylori Infection in Pediatrics

Cited by 4 publications

References 3 publications

Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Juli 2022 – AWMF-Registernummer: 021–001

Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – Juli 2022 – AWMF-Registernummer: 021–001

Therapeutic eradication choices inHelicobacter pyloriinfection in children

Update S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)

Contact Info

Product

Resources

About